Pretargeted radioimmunotherapy for hematologic and other malignancies

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 2, 2010, Pages 125-142

  Walter, Roland B ^a,b   Press, Oliver W ^a,b   Pagel, John M ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antibody; Cancer; Immunotherapy; Leukemia; Lymphoma; Pretargeting; Radioimmunotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID BI 213; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90; ANTINEOPLASTIC AGENT; BIOTIN; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CD45 ANTIBODY STREPTAVIDIN FUSION PROTEIN; EPITHELIAL CELL ADHESION MOLECULE; EPRATUZUMAB; GEMCITABINE; HAPTEN ANTIBODY; IODINE 131; MESOTHELIN; MILATUZUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CC49; MONOCLONAL ANTIBODY NR LU 10; MONOCLONAL ANTIBODY PAM4; MUCIN 1; PENTETATE INDIUM IN 111; PLATINUM DERIVATIVE; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY STREPTAVIDIN FUSION PROTEIN; STREPTAVIDIN; TENASCIN MONOCLONAL ANTIBODY; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN SPECIFICITY; B CELL LYMPHOMA; BINDING AFFINITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BURKITT LYMPHOMA; CANCER PATIENT; CLINICAL TRIAL; COLON CANCER; COLON CARCINOMA; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EPIDERMOID TUMOR; FEASIBILITY STUDY; GLIOMA; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LIVER TOXICITY; LYMPHOMA; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOIMMUNOTHERAPY; REVIEW; RISK BENEFIT ANALYSIS; SOLID TUMOR; THYROID MEDULLARY CARCINOMA; WHOLE BODY RADIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HEMATOLOGIC NEOPLASMS; HUMANS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77951962289     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2010.0759     Document Type: Review

References (163)

1. Park SI, Press OW. Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies. Curr Opin Hematol 2007;14:632.
2. DeNardo GL, DeNardo SJ, Balhorn R. Systemic radiotherapy can cure lymphoma: A paradigm for other malignancies? Cancer Biother Radiopharm 2008;23:383.
3. Green DJ, Pagel JM, Pantelias A, et al. Pretargeted radioimmunotherapy for B-cell lymphomas. Clin Cancer Res 2007;13:5598s.
4. Strand SE, Zanzonico P, Johnson TK. Pharmacokinetic modeling. Med Phys 1993;20:515.
5. Chinol M, Grana C, Gennari R, et al. Pretargeted radio of cancer. In: Abrams PG, Fritzberg AR, eds. Radioimmunotherapy of Cancer. New York: Marcel Dekker, 2000;169.
6. Slavin-Chiorini DC, Horan Hand P, Greiner JW. Antibodies and novel constructs for tumor targeting. In: Abrams PG, Fritzberg AR, eds. Radioimmunotherapy of Cancer. New York: Marcel Dekker, 2000;137.
7. Pagel JM, Boerman OC, Breitz HB, et al. Targeted radionuclide therapy of cancer. In: Oldham RK, Dillman RO, eds. Principles of Cancer Biotherapy, 5th ed. New York: Springer, 2009;463.
8. Chang CH, Sharkey RM, Rossi EA, et al. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol Cancer Ther 2002;1:553.
9. 90Y radioimmunotherapy in a mouse xenograft model [abstr]. J Immunother 1994;16:158.
10. Goldenberg DM, Chatal JF, Barbet J, et al. Cancer imaging and therapy with bispecific antibody pretargeting. Update Cancer Ther 2007;2:19.
11. Milenic DE, Yokota T, Filpula DR, et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 1991;51:6363.
12. Yokota T, Milenic DE, Whitlow M, et al. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402.
13. Schott ME, Milenic DE, Yokota T, et al. Differential metabolic patterns of iodinated versus radiomet al. chelated anticarcinoma single-chain Fv molecules. Cancer Res 1992;52:6413.
14. Buist MR, Kenemans P, den Hollander W, et al. Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F (ab') 2 fragments in ovarian carcinoma patients. Cancer Res 1993;53:5413.
15. Goodwin DA, Meares CF. Pretargeting: General principles; October 10-12, 1996. Cancer 1997;80 (suppl) : 2675.
16. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A 2000;97:1802.
17. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 2001;98:2535.
18. Pagel JM, Hedin N, Subbiah K, et al. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 2003;101:2340.
19. Goldenberg DM, Sharkey RM, Paganelli G, et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006;24:823.
20. Goodwin DA, Meares CF. Advances in pretargeting biotechnology. Biotechnol Adv 2001;19:435.
21. Boerman OC, van Schaijk FG, Oyen WJ, et al. Pretargeted radioimmunotherapy of cancer: Progress step by step. J Nucl Med 2003;44:400.
22. Sharkey RM, Goldenberg DM. Novel radioimmunopharmaceuticals for cancer imaging and therapy. Curr Opin Investig Drugs 2008;9:1302.
23. Hawkins GA, McCabe RP, Kim CH, et al. Delivery of radionuclides to pretargeted monoclonal antibodies using dihydrofolate reductase and methotrexate in an affinity system. Cancer Res 1993;53 (suppl) : 2368.
24. Reardan DT, Meares CF, Goodwin DA, et al. Antibodies against met al. chelates. Nature 1985;316:265.
25. Schuhmacher J, Klivenyi G, Matys R, et al. Multistep tumor targeting in nude mice using bispecific antibodies and a gallium chelate suitable for immunoscintigraphy with positron emission tomography. Cancer Res 1995;55:115.
26. Klivenyi G, Schuhmacher J, Patzelt E, et al. Gallium-68 chelate imaging of human colon carcinoma xenografts pretargeted with bispecific anti-CD44V6/anti-gallium chelate antibodies. J Nucl Med 1998;39:1769.
27. Goodwin DA, Meares CF, McTigue M, et al. Monoclonal antibody hapten radiopharmaceutical delivery. Nucl Med Commun 1986;7:569.
28. Goodwin DA, Meares CF, McCall MJ, et al. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med 1988;29:226.
29. Mirallié E, Saï-Maurel C, Faivre-Chauvet A, et al. Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody. Eur J Nucl Med Mol Imaging 2005;32:901.
30. Rossi EA, Sharkey RM, McBride W, et al. Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. Clin Cancer Res 2003;9:3886S.
31. Rossi EA, Chang CH, Losman MJ, et al. Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells. Clin Cancer Res 2005;11 (suppl) : 7122s.
32. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005;46 (suppl) : 115S.
33. Le Doussal JM, Martin M, Gautherot E, et al. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: Enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989;30:1358.
34. Barbet J, Kraeber-Bodere F, Vuillez JP, et al. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm 1999;14:153.
35. (188)Re-labeled peptide. Bioconjug Chem 2000;11:842.
36. Goodwin DA, Meares CF, McTigue M, et al. Pretargeted immunoscintigraphy: Effect of hapten valency on murine tumor uptake. J Nucl Med 1992;33:2006.
37. Gautherot E, Le Doussal JM, Bouhou J, et al. Delivery of therapeutic doses of radioiodine using bispecific antibodytargeted bivalent haptens. J Nucl Med 1998;39:1937.
38. Boerman OC, Kranenborg MH, Oosterwijk E, et al. Pretargeting of renal cell carcinoma: Improved tumor targeting with a bivalent chelate. Cancer Res 1999;59:4400.
39. Morel A, Darmon M, Delaage M. Recognition of imidazole and histamine derivatives by monoclonal antibodies. Mol Immunol 1990;27:995.
40. Janevik-Ivanovska E, Gautherot E, Hillairet de Boisferon M, et al. Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy. Bioconjug Chem 1997;8:526.
41. Sharkey RM, McBride WJ, Karacay H, et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res 2003;63:354.
42. Morandeau L, Benoist E, Loussouarn A, et al. Synthesis of new bivalent peptides for applications in the Affinity Enhancement System. Bioconjug Chem 2005;16:184.
43. Rossi EA, Goldenberg DM, Cardillo TM, et al. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A 2006;103:6841.
44. Chang CH, Rossi EA, Goldenberg DM. The dock and lock method: A novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin Cancer Res 2007;13 (suppl) : 5586s.
45. Goldenberg DM, Rossi EA, Sharkey RM, et al. Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med 2008;49:158.
46. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med 1987;28:1294.
47. Wilchek M, Bayer EA. The avidin-biotin complex in bioanalytical applications. Anal Biochem 1988;171:1.
48. Sung C, van Osdol WW, Saga T, et al. Streptavidin distribution in metastatic tumors pretargeted with a biotinylated monoclonal antibody: Theoretical and experimental pharmacokinetics. Cancer Res 1994;54:2166.
49. Green NM. Avidin, I. The use of (14-C) biotin for kinetic studies and for assay. Biochem J 1963;89:585.
50. Goodwin DA, Meares CF, Osen M. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system. J Nucl Med 1998;39:1813.
51. Sharkey RM, Karacay H, Griffiths GL, et al. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer: Studies in a human colon cancer xenograft model. Bioconjug Chem 1997;8:595.
52. Chauhan J, Dakshinamurti K. Purification and characterization of human serum biotinidase. J Biol Chem 1986;261:4268.
53. Foulon CF, Alston KL, Zalutsky MR. Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy. Nucl Med Biol 1998;25:81.
54. Sabatino G, Chinol M, Paganelli G, et al. A new biotin derivative-DOTA conjugate as a candidate for pretargeted diagnosis and therapy of tumors. J Med Chem 2003;46:3170.
55. Urbano N, Papi S, Ginanneschi M, et al. Evaluation of a new biotin-DOTA conjugate for pretargeted antibodyguided radioimmunotherapy (PAGRIT). Eur J Nucl Med Mol Imaging 2007;34:68.
56. Sung C, van Osdol WW. Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidin-biotin binding. J Nucl Med 1995;36:867.
57. Theodore LJ, Fritzberg AR, Schultz JE, et al. Evolution of a pretarget radioimmunotherapeutic regimen. In: Abrams PG, Fritzberg AR, eds.) Radioimmunotherapy of Cancer. New York: Marcel Dekker, 2000;195.
58. Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982;51:531.
59. Moi MK, Meares CF, DeNardo SJ. The peptide way to macrocyclic bifunctional chelating agents: Synthesis of 2-(p-nitrobenzyl)-1,4,7,10- tetraazacyclododecane N, N′, N′′, N′′′- tetraacetic acid and the study of its yttrium (III) complex. J Am Chem Soc 1988;10:6266.
60. Su FM, Beaumier P, Axworthy D, et al. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator. Nucl Med Biol 2005;32:741.
61. Yao Z, Zhang M, Garmestani K, et al. Pretargeted alpha emitting radioimmunotherapy using (213) Bi 1,4,7,10-tetraazacyclododecane-N, N′, N′′, N′′′-tetraacetic acid-biotin. Clin Cancer Res 2004;10:3137.
62. Lindegren S, Andersson H, Jacobsson L, et al. Synthesis and biodistribution of 211At-labeled, biotinylated, and charge-modified poly-L-lysine: Evaluation for use as an effector molecule in pretargeted intraperitoneal tumor therapy. Bioconjug Chem 2002;13:502.
63. Lindegren S, Karlsson B, Jacobsson L, et al. (211) At-labeled and biotinylated effector molecules for pretargeted radioimmunotherapy using poly-l - and poly-d-Lysine as multicarriers. Clin Cancer Res 2003;9:3873S.
64. Yao Z, Zhang M, Kobayashi H, et al. Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase. J Nucl Med 1995;36:837.
65. Schultz J, Lin Y, Sanderson J, et al. A tetravalent singlechain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res 2000;60:6663.
66. Goshorn S, Sanderson J, Axworthy D, et al. Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy. Cancer Biother Radiopharm 2001;16:109.
67. Lin Y, Pagel JM, Axworthy D, et al. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. Cancer Res 2006;66:3884.
68. Bos ES, Kuijpers WH, Meesters-Winters M, et al. In vitro evaluation of DNA-DNA hybridization as a two-step approach in radioimmunotherapy of cancer. Cancer Res 1994;54:3479.
69. Kuijpers WH, Bos ES, Kaspersen FM, et al. Specific recognition of antibody-oligonucleotide conjugates by radiolabeled antisense nucleotides: A novel approach for two-step radioimmunotherapy of cancer. Bioconjug Chem 1993;4:94.
70. 99mTc. Nucl Med Biol 2003;30:207.
71. 99mTc morpholino pretargeting in mice. Nucl Med Commun 2003;24:697.
72. 188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue. Clin Cancer Res 2006;12:4958.
73. He J, Rusckowski M, Wang Y, et al. Optical pretargeting of tumor with fluorescent MORF oligomers. Mol Imaging Biol 2007;9:17.
74. He J, Liu G, Dou S, et al. An improved method for covalently conjugating morpholino oligomers to antitumor antibodies. Bioconjug Chem 2007;18:983.
75. Liu G, Dou S, He J, et al. Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice. Eur J Nucl Med Mol Imaging 2007;34:237.
76. Goldenberg DM, Chang CH, Sharkey RM, et al. Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 2003;30:777.
77. Paganelli G, Chinol M. Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 2003;30:773.
78. Breitz HB, Weiden PL, Beaumier PL, et al. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. J Nucl Med 2000;41:131.
79. Paganelli G, Grana C, Chinol M, et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 1999;26:348.
80. Le Doussal JM, Chetanneau A, Gruaz-Guyon A, et al. Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: Pharmacokinetics, biodistribution, scintigraphy and immune response. J Nucl Med 1993;34:1662.
81. Kraeber-Bodéré F, Faivre-Chauvet A, Ferrer L, et al. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res 2003;9 (suppl) : 3973S.
82. Liu G, Dou S, Pretorius PH, et al. Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF. Eur J Nucl Med Mol Imaging 2008;35:272.
83. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002;43:693.
84. Subbiah K, Hamlin DK, Pagel JM, et al. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med 2003;44:437.
85. Pagel JM, Lin Y, Hedin N, et al. Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas. Blood 2006;108:328.
86. Pagel JM, Pantelias A, Hedin N, et al. Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas. Cancer Res 2007;67:5921.
87. Pantelias A, Pagel JM, Hedin N, et al. Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas. Blood 2007;109:4980.
88. Pagel JM, Orgun N, Hamlin DK, et al. A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood 2009;113:4903.
89. Press OW, Farr AG, Borroz KI, et al. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 1989;49:4906.
90. Zhang M, Zhang Z, Garmestani K, et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci U S A 2003;100:1891.
91. Zhang M, Yao Z, Garmestani K, et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. Blood 2002;100:208.
92. Sharkey RM, Karacay H, Chang CH, et al. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia 2005;19:1064.
93. Sharkey RM, Karacay H, Litwin S, et al. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res 2008;68:5282.
94. Hillairet de Boisferon M, Raguin O, Dussaillant M, et al. Enhanced targeting specificity to tumor cells by simultaneous recognition of two antigens. Bioconjug Chem 2000;11:452.
95. Sharkey RM, Karacay H, Johnson CR, et al. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. J Nucl Med 2009;50:444.
96. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation. N Engl J Med 1975;292:832.
97. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. Blood 1990;76:1867.
98. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens. Blood 1991;77:1660.
99. Clift RA, Buckner CD, Appelbaum FR, et al. Long-term follow-up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia. Blood 1998;92:1455.
100. Kotzerke J, Bunjes D, Scheinberg DA. Radioimmunoconjugates in acute leukemia treatment: The future is radiant. Bone Marrow Transplant 2005;36:1021.
101. Pagel JM. Radioimmunotherapeutic approaches for leukemia: The past, present and future. Cytotherapy 2008;10:13.
102. Omary MB, Trowbridge IS, Battifora HA. Human homologue of murine T200 glycoprotein. J Exp Med 1980;152:842.
103. Dahlke MH, Larsen SR, Rasko JE, et al. The biology of CD45 and its use as a therapeutic target. Leuk Lymphoma 2004;45:229.
104. Andres TL, Kadin ME. Immunologic markers in the differential diagnosis of small round cell tumors from lymphocytic lymphoma and leukemia. Am J Clin Pathol 1983;79:546.
105. Nakano A, Harada T, Morikawa S, et al. Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines. Acta Pathol Jpn 1990;40:107.
106. Taetle R, Ostergaard H, Smedsrud M, et al. Regulation of CD45 expression in human leukemia cells. Leukemia 1991;5:309.
107. Press OW, Howell-Clark J, Anderson S, et al. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 1994;83:1390.
108. van der Jagt RHC, Badger CC, Appelbaum FR, et al. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. Cancer Res 1992;52:89.
109. Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of (131) I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999;94:1237.
110. Glatting G, Muller M, Koop B, et al. Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia. J Nucl Med 2006;47:1335.
111. Pagel JM, Appelbaum FR, Eary JF, et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 2006;107:2184.
112. Pagel JM, Matthews DC, Kenoyer A, et al. Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia. Cancer Res 2009;69:185.
113. Pagel JM, Hedin N, Drouet L, et al. Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. Blood 2008;111:2261.
114. Green DJ, Pagel JM, Nemecek ER, et al. Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates. Blood 2009;114:1226.
115. Gautherot E, Bouhou J, Le Doussal JM, et al. Therapy for colon carcinoma xenografts with bispecific antibodytargeted, iodine-131-labeled bivalent hapten. Cancer 1997;80 (suppl) :2618.
116. van Schaijk FG, Oosterwijk E, Soede AC, et al. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen χ anti-indium-labeled diethylenetriaminepentaacetic acid antibody. Clin Cancer Res 2005;11 (suppl) : 7130s.
117. Gautherot E, Rouvier E, Daniel L, et al. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten. J Nucl Med 2000;41:480.
118. Kraeber-Bodéré F, Saï-Maurel C, Campion L, et al. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol Cancer Ther 2002;1:267.
119. Kraeber-Bodéré F, Faivre-Chauvet A, Saï-Maurel C, et al. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: Comparison of iodine 131-labeled F (ab') 2 and pretargeted bivalent hapten and evaluation of repeated injections. Clin Cancer Res 1999;5 (suppl) : 3183s.
120. Gautherot E, Kraeber-Bodere F, Daniel L, et al. Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with 131I-labeled bivalent hapten and anti-CEA χ antihapten bispecific antibody. Clin Cancer Res 1999;5 (suppl) : 3177s.
121. Gestin JF, Loussouarn A, Bardies M, et al. Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: Biodistribution and dosimetry studies. J Nucl Med 2001;42:146.
122. Sharkey RM, Karacay H, Richel H, et al. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin Cancer Res 2003;9 (suppl) : 3897S.
123. Sharkey RM, Cardillo TM, Rossi EA, et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 2005;11:1250.
124. Karacay H, Brard PY, Sharkey RM, et al. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res 2005;11:7879.
125. Li GP, Zhang H, Zhu CM, et al. Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma. World J Gastroenterol 2005;11:6288.
126. Strnad J, Hamilton AE, Beavers LS, et al. Molecular cloning and characterization of a human adenocarcinoma/epithelial cell surface antigen complementary DNA. Cancer Res 1989;49:314.
127. Szala S, Froehlich M, Scollon M, et al. Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc Natl Acad Sci U S A 1990;87:3542.
128. Lewis MR, Wang M, Axworthy DB, et al. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. J Nucl Med 2003;44:1284.
129. Gold DV, Lew K, Maliniak R, et al. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin. Int J Cancer 1994;57:204.
130. Gold DV, Karanjawala Z, Modrak DE, et al. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res 2007;13:7380.
131. Mariani G, Molea N, Bacciardi D, et al. Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer. Cancer Res 1995;55 (suppl) : 5911s.
132. 90) Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin Cancer Res 2003;9:3929S.
133. Cardillo TM, Karacay H, Goldenberg DM, et al. Improved targeting of pancreatic cancer: Experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy. Clin Cancer Res 2004;10:3552.
134. Gold DV, Goldenberg DM, Karacay H, et al. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Cancer Res 2008;68:4819.
135. Albrecht H, DeNardo GL, DeNardo SJ. Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers. Q J Nucl Med Mol Imaging 2007;51:304.
136. Graves SS, Dearstyne E, Lin Y, et al. Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res 2003;9:3712.
137. Buchsbaum DJ, Khazaeli MB, Axworthy DB, et al. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein. Clin Cancer Res 2005;11:8180.
138. Förster GJ, Santos EB, Smith-Jones PM, et al. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: Strategies for reduction of the renal dose. J Nucl Med 2006;47:140.
139. Sato N, Hassan R, Axworthy DB, et al. Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. J Nucl Med 2005;46:1201.
140. De Santis R, Albertoni C, Petronzelli F, et al. Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody. Clin Cancer Res 2006;12:2191.
141. Moosmayer D, Berndorff D, Chang CH, et al. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors. Clin Cancer Res 2006;12:5587.
142. van Schaijk FG, Oosterwijk E, Molkenboer-Kuenen JD, et al. Pretargeting with bispecific anti-renal cell carcinoma χ anti-DTPA (In) antibody in 3 RCC models. J Nucl Med 2005;46:495.
143. van Schaijk FG, Boerman OC, Soede AC, et al. Comparison of IgG and F (ab') 2 fragments of bispecific anti-RCCxanti-DTIn-1 antibody for pretargeting purposes. Eur J Nucl Med Mol Imaging 2005;32:1089.
144. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G 250 recognizes a determinant present in renalcell carcinoma and absent from normal kidney. Int J Cancer 1986;38:489.
145. Kranenborg MH, Boerman OC, Oosterwijk-Wakka JC, et al. Development and characterization of anti-renal cell carcinoma χ antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma. Cancer Res 1995;55 (suppl) : 5864s.
146. (188)Re. Clin Cancer Res 2003;9 (suppl) : 3880S.
147. van Schaijk FG, Broekema M, Oosterwijk E, et al. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting. J Nucl Med 2005;46:1016.
148. Pastan I, Lovelace ET, Gallo MG, et al. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res 1991;51:3781.
149. Yao Z, Zhang M, Axworthy DB, et al. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90) Y-labeled 1, 4, 7, 10-tetraazacyclododecane-N, N′, N′′, N′′′-tetraacetic acid (DOTA) - biotin. Cancer Res 2002;62:5755.
150. Weiden PL, Breitz HB, Press O, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL) : Initial phase I/II study results. Cancer Biother Radiopharm 2000;15:15.
151. Forero A, Weiden PL, Vose JM, et al. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood 2004;104:227.
152. Palumbo G, Grana CM, Cocca F, et al. Pretargeted antibodyguided radioimmunotherapy in a child affected by resistant anaplastic large cell lymphoma. Eur J Haematol 2007;79:258.
153. Kraeber-Bodéré F, Bardet S, Hoefnagel CA, et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: Preliminary results of a phase I/II clinical trial. Clin Cancer Res 1999;5 (suppl) : 3190s.
154. Vuillez JP, Kraeber-Bodere F, Moro D, et al. Radioimmunotherapy of small cell lung carcinoma with the twostep method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: Results of a phase I/II trial. Clin Cancer Res 1999;5 (suppl) : 3259s.
155. Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, et al. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med 2006;47:247.
156. Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: A collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006;24:1705.
157. Barbet J, Campion L, Kraeber-Bodere F, et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005;90:6077.
158. Forero-Torres A, Shen S, Breitz H, et al. Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein. Cancer Biother Radiopharm 2005;20:379.
159. Shen S, Forero A, LoBuglio AF, et al. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J Nucl Med 2005;46:642.
160. Knox SJ, Goris ML, Tempero M, et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 2000;6:406.
161. 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin. Cancer Biother Radiopharm 1999;14:381.
162. Grana C, Chinol M, Robertson C, et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: A pilot study. Br J Cancer 2002;86:207.
163. Paganelli G, Bartolomei M, Ferrari M, et al. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: Phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 2001;16:227.